Vivek Subbiah: Super thrilled to deliver the keynote lecture on “Precision Oncology: Future is now” at the Binaytara Foundation.

Paul Markovich: Last week, I was in Washington, D.C. meeting with federal policymakers to discuss some of Blue Shield of California’s key initiatives.

Daniel Stover: If we are going to ‘turn the page’ on breast cancer, we must address disparities in outcomes at multiple levels.

Michael Dickinson: In our article, we report on the development of rapid CART – YTB323, also known as rapcabtagene autoleucel.

Cristiane Bergerot: We delved into racial and ethnic differences in patients’ perceptions of genomic profiling for prostate, urothelial, or kidney cancer.

Todd Scarbrough: Dear radiation oncology, there is a much higher rate of radiation oncologist production versus the rate of new cancer incidence- A REALLY LONG BUT COOL Thread

Sophie Castell: DRD is a game changer and will make a tremendous difference to patients’ quality of life.

Justin Stebbing: Our study in Nature Communications has been highlighted by lots of news outlets focusing on age of first pregnancy as a major risk for breast cancer, and how we explain this via clonal patches in tissues.

Vivek Subbiah: Super thrilled to share our paper – Variant of allele frequency: a decision-making tool in precision oncology?

Uta Dirksen: Proud to announce that our paper on local therapy in Ewing sarcoma is now published in EJC!